Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is in Phase 2 trials for moderate-to-severe psoriasis, featuring half-life extension technology that supports potential once-per-year dosing. The co-lead program, ORKA-002, targets interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and conditions like hidradenitis suppurativa, with Phase 1 data indicating a half-life of 75-80 days to enable twice-yearly or quarterly dosing. The company also advances ORKA-003 targeting an undisclosed pathway. These biologics aim to provide high-affinity binding, extended exposure, and reduced dosing frequency to improve patient outcomes in chronic skin and autoimmune diseases. Founded in 2004 and headquartered in Menlo Park, California, Oruka Therapeutics operates in the biotechnology sector, focusing on dermatology and immunology pipelines to address unmet needs in the inflammatory disease market.